Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tetanus toxoid (Keymen İlaç)
- Development stage
- Unknown
- Lead developer
- Serum Institute of India
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Tetanus toxoid, adsorbed is a toxoid vaccine developed by Keymen İlaç Sanayi ve Ticaret for the prevention of tetanus. It contains the formaldehyde-inactivated toxin (toxoid) of *Clostridium tetani* adsorbed onto an aluminum hydroxide adjuvant to enhance the immune response. The vaccine works by inducing the production of specific neutralizing antibodies (antitoxins) that protect the individual against the effects of the tetanus toxin. It is approved for active immunization against tetanus in both children and adults and is typically administered via intramuscular injection.
- Brand names
- Adsorbed Tetanus Vaccine
- Other names
- Tetanoz AşısıAdsorbed Tetanus Vaccine-Keymen
Beyond the preview
Go deeper on tetanus toxoid (Keymen İlaç).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tetanus toxoid (Keymen İlaç).